It is trading at $23.42 much lower than the 50 day moving average of $41.24 and impressively lower than the 200 day moving average of $39.09. The 50 day moving average went down $-17.82 or -43.22% and the 200 day average was down $-15.67. (NASDAQ:DBVT) shares saw light trading volume with 668K shares changing hands in the last trading session. Trading volume was down 44.21% under the stocks average daily volume.
Short traders are more bearish on shares of the company of late if you evaluate the change in short interest. The firm experienced a rise in short interest of 19.20% as of October 13, 2017 from the last reporting period. Short interest grew from 1,055,107 to 1,257,727 over that period. Days to cover decreased 0.0 to 4.0 and the short interest percentage is 0.03% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (DBVT). As of quarter end SIT Investment Associates Inc had sold 700 shares trimming its holdings by 3.6%. The value of the investment in DBV Technologies S.A. – America went from $698,000 to $800,000 a change of $102,000 quarter over quarter. First Manhattan Co divested its ownership by selling 80,000 shares a decrease of 38.7% from 06/30/2017 to 09/30/2017. First Manhattan Co now controls 126,669 shares valued at $5,375,000. The value of the position overall is down by 27.2%.
As of the end of the quarter Victory Capital Management Inc had acquired a total of 740 shares growing its position 9.0%. The value in dollars increased from $292,000 to $379,000 a change of 29.8% since the last quarter. As of the end of the quarter Simplex Trading, LLC had acquired 2,616 shares growing its stake by 44.3%. The value of the company’s investment in DBV Technologies S.A. – America increased from $210,000 to $361,000 increasing 71.9% quarter to quarter.
October 2 investment analysts at Citigroup held the company rating at “Buy” but raised the price expectation from $43.00 to $57.00. On October 6 Morgan Stanley maintained a company rating of “Overweight” and moved up the price target to $72.00 from $67.00.
October 23 investment analysts at Leerink Swann kept the stock rating at “Overweight” and lowered the price expectation to $30.00 from $56.00. On October 23 Barclays held the stock rating at “Overweight” but lowered the price target to $30.00 from $58.00.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product which is in Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trials for the treatment of CMPA and milk-induced eosinophilic esophagitis; and Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy. Its other earlier stage product development programs include a booster vaccine for pertussis, as well as treatments for Crohn’s disease and respiratory syncytial virus. DBV Technologies S.A. has collaboration with NestlÃ© Health Science to develop and commercialize a novel diagnostic test for pediatric milk allergy. The company was founded in 2002 and is headquartered in Montrouge, France..